Clinical trials: Vascular Patients
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Peripheral Arterial Disease
Measurement of Tissue Oxygen Saturation in Chronic Critical Limb Ischemia
Near-infrared spectroscopy can be used to determine the relative oxygen saturation in tissues up to 2cm below the skin. It has been investigated, with success, in cerebral, gastrointestinal, and muscle tissue, and shows promise…
- Trial name
- NCT00224328
- Testing
- ODISsey Tissue Oximeter
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- ViOptix Canada
Non-valvular Atrial Fibrillation (NVAF)
Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation
The purpose of the study is to evaluate the safety and effectiveness of Xarelto in renally impaired patients with NVAF under routine practice conditions.
- Trial name
- XARENAL (NCT03746301)
- Testing
- Rivaroxaban(Xarelto,BAY 59-7939)
- Where
- South Korea
- Volunteers
- 924 people
- Sponsor
- Bayer
Multiple Myeloma
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
This observational study will observe the degree of the quality of life in patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and Treatment of…
- Trial name
- NCT01021592
- Testing
- bortezomib
- Volunteers
- 140 people
- Sponsor
- Janssen Korea, Ltd., Korea
Hypertension
High Dose BAYA1040 CR: a Long Term Extension Study
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040 CR 80 mg/day (40 mg twice daily) in patients with essential hypertension for whom the test drug is tolerable during the 8…
- Trial name
- NCT01355367
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 22 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Bayer
Renal Cell Carcinoma
Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.
The purpose of the protocol is to assess the Overall Survival (OS) at 1 year in patients after cabozantinib initiation.
- Trial name
- CAROLINE (NCT04609800)
- Sponsor
- Ipsen
Essential Hypertension
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately…
- Trial name
- NCT06416865
- Testing
- AJU-C52L, AJU-C52, C52R1L, C52R1M
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- AJU Pharm Co., Ltd.
Coronary Artery Disease
Serial OCT Evaluation of Tissue Coverage in Patients Submitted to Inspiron Drug Eluting Stent Implantation
Prospective, multicentric, single-arm study to evaluate fast and effective tissue repair in patients undergone percutaneous coronary intervention with drug eluting stent Inspiron.
- Trial name
- REPAIR (NCT03269461)
- Testing
- Angiography and Optical Coherence Tomography evaluations
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Scitech Produtos Medicos SA
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with connective tissue disease-associated pulmonary arterial hypertension to determine the recommended dose range and evaluate the…
- Trial name
- NCT02657356
- Testing
- Bardoxolone methyl capsules
- Where
- 106 sites in United States, Argentina and 13 more
- Volunteers
- 202 people
- Sponsor
- Biogen
Peripheral Vascular Diseases
Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia
The purpose of this study is to assess the safety and the immediate effect of the VascuActive device on patients with peripheral vascular disease and limb ischemia.
- Trial name
- NCT01014377
- Testing
- VascuActive
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- VascuActive LTD
Advanced Solid Tumors
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.
- Trial name
- NCT00793975
- Testing
- IMC-1121B, 1121B
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Open-Angle Glaucoma, Ocular Hypertension
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
To determine the safety and IOP-lowering ability of a test compound in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00069719
- Testing
- Glaucoma therapy
- Where
- United States
- Sponsor
- Alcon Research
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
- Trial name
- NCT01785472
- Testing
- LCZ696, Olmesartan
- Where
- 50 sites in China, Hong Kong and 5 more
- Volunteers
- 1,438 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary…
- Trial name
- PARAMOUNT (NCT06713239)
- Testing
- Cleerly Labs and Cleerly ISCHEMIA
- Where
- 21 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Cleerly, Inc.
Pulmonary Hypertension
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)
Characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension
- Trial name
- PreVailPH2 OUS (NCT06495970)
- Testing
- Gradient Denervation System
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Gradient Denervation Technologies
Abdominal Aortic Aneurysms
ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA
This is a Prospective Registry study to collect imaging and clinical data both on patients with aortic aneurysm disease undergoing serial monitoring and on patients pre and post-endovascular repair, using ViTAA (The Sponsor)…
- Trial name
- NCT05004051
- Testing
- ViTAA Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- ViTAA Medical Solutions
Hypertension
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates.
- Trial name
- REAL-HTN (NCT07465666)
- Where
- 4 sites in United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome
Fondaparinux EU-RMP (Adherence)
Fondaparinux, a synthetic and specific factor Xa inhibitor, was granted an ACS indication by Health Canada in March 2007 and by the EMEA in September 2007.
- Trial name
- NCT01406301
- Testing
- fondaparinux
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass…
- Trial name
- NCT00042081
- Testing
- CGT003 (E2F Duplex Decoy)
- Where
- 154 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Anesiva, Inc.
Multiple Myeloma
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
This is a phase II study to determine the efficacy following treatment with Aplidin® 5 mg/m2, given as a 3 hours intravenous infusion every 2 weeks, in patients with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT00229203
- Testing
- Plitidepsin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- PharmaMar
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.